Allergan, Inc. Patent applications |
Patent application number | Title | Published |
20160102088 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 - This invention is directed to a compound of Formula I | 04-14-2016 |
20160102081 | Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors - This invention is directed to a compound of Formula I | 04-14-2016 |
20160102080 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS - This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders. | 04-14-2016 |
20160102077 | Indole-3-Carboxamides as Kinase Inhibitors - This invention is directed to a compound of Formula I | 04-14-2016 |
20160096837 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 04-07-2016 |
20160096832 | KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 04-07-2016 |
20160096828 | Indole-1-Carboxamides as Kinase Inhibitors - This invention is directed to a compound of Formula I | 04-07-2016 |
20160082007 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS - The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α | 03-24-2016 |
20160051555 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds: | 02-25-2016 |
20150290170 | KETOROLAC-CONTAINING SUSTAINED RELEASE DRUG DELIVERY SYSTEMS - Biodegradable intraocular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye for an extended period of time at a substantially constant rate are described. | 10-15-2015 |
20150283240 | STABILIZED COMPOSITIONS COMPRISING A THERAPEUTICALLY ACTIVE AGENT AND AN OXIDIZING PRESERVATIVE - Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein. | 10-08-2015 |
20150274658 | THERAPEUTIC LACTAMS - Disclosed herein is a compound having a structure | 10-01-2015 |
20150272948 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS - The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α | 10-01-2015 |
20150238698 | ASPIRATION SYRINGE ACCESSORY - A device is provided for facilitating an aspiration procedure during a dermal filler injection treatment. The device can be connected to a dermal filler syringe plunger, and includes a thumb stop element for engaging a physician's thumb. | 08-27-2015 |
20150231140 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds: | 08-20-2015 |
20150209276 | EXTENDED RELEASE BIODEGRADABLE OCULAR IMPLANTS - Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer. | 07-30-2015 |
20150175586 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION - This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension. | 06-25-2015 |
20150174292 | Thermoresponsive Compositions for Dermatological Use and Methods Thereof - The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions. | 06-25-2015 |
20150174062 | BIODEGRADABLE DRUG DELIVERY SYSTEM - A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics. | 06-25-2015 |
20150158895 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) - The invention relates to compounds of the formula | 06-11-2015 |
20150148395 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 05-28-2015 |
20150119367 | Phosphate Esters of Bimatoprost and the Prostamides - Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same. | 04-30-2015 |
20150104491 | SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY - The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days. | 04-16-2015 |
20150086531 | METHODS FOR MODIFYING PROGRESSION OF OSTEOARTHRITIS - Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein. | 03-26-2015 |
20150080845 | POLYMER SYSTEM FOR SECURING IMPLANTS IN SYRINGE NEEDLES - Disclosed herein are methods of delivering implants to a target organ with an implant administration device, where the implant administration device includes a polymer retainer. Methods of making polymer retainers and methods of securing an implant within an implant administration device using a polymer retainer are also disclosed herein. | 03-19-2015 |
20150080466 | DIPHENYL UREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS - The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2. | 03-19-2015 |
20150065433 | CYCLOSPORIN ANALOGS - Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions. | 03-05-2015 |
20150064147 | CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION - Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component. | 03-05-2015 |
20150057261 | AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-26-2015 |
20150057253 | ALKYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-26-2015 |
20150056261 | SILK MEDICAL DEVICES - Laminate medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble silk film. | 02-26-2015 |
20150051186 | ARYL AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-19-2015 |
20150051176 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors | 02-19-2015 |
20150045341 | DISUBSTITUTED ARYL AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to disubstituted aryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 02-12-2015 |
20150025021 | DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR MODULATORS - The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor. | 01-22-2015 |
20140378492 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 12-25-2014 |
20140371320 | COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 12-18-2014 |
20140371200 | ALKENE AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to alkene azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 12-18-2014 |
20140364494 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE - Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition. | 12-11-2014 |
20140364379 | TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY - Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent. | 12-11-2014 |
20140363457 | 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to 2-thio-1,3,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 12-11-2014 |
20140357705 | SUBSTITUTED CYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein are compounds having a formula: | 12-04-2014 |
20140357609 | OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES - Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described. | 12-04-2014 |
20140356438 | PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS - Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time. | 12-04-2014 |
20140350518 | SYRINGE EXTRUSION ACCESSORY - Described herein are syringe extrusion accessories comprising: a handle operatively coupled to an attachment portion configured to attach to a syringe; and at least one prawl operatively coupled to the handle and configured to engage with a plunger of the syringe, wherein the syringe extrusion accessory is configured to transfer a substantially perpendicular force applied to the handle to an axial force to push the plunger and extrude a product from the syringe. | 11-27-2014 |
20140350517 | INJECTION DEVICE WITH STRESS PROTECTION - Described are devices and systems for protection of injectable substances such as adipose cells from excessive stress or pressure during injection procedures. Further described are stress control mechanisms for detecting and/or controlling stress or pressure within injection devices. | 11-27-2014 |
20140350516 | MECHANICAL SYRINGE ACCESSORY - Described herein are syringe accessories that can be attached to standard syringes. These accessories utilize one or more mechanisms that can provide at least one additional sensory feedback to the user when performing an aliquot or dosed injection. In other embodiments, the accessories can prevent overdosing. | 11-27-2014 |
20140329874 | ALPHA ADRENERGIC AGONISTS FOR THE TREATMENT OF TISSUE TRAUMA - The present invention provides a method of treating tissue trauma (such as damage from radiation (such as solar and ultraviolet radiation), wounds, bruising, burns, blisters, excoriations, incisions, excisions, and ulcers) in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist (such as oxymetazoline hydrochloride). The present invention also provides a method for alleviating the pain or discomfort associated with aesthetic or plastic surgery or cosmetology procedures in a subject comprising administering said alpha adrenergic agonist. | 11-06-2014 |
20140329852 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS - The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 11-06-2014 |
20140323558 | THERAPEUTIC AGENTS - The invention provides well-defined compounds that are either EP | 10-30-2014 |
20140323510 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein is a compound of the formula | 10-30-2014 |
20140322206 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 10-30-2014 |
20140322197 | METHODS FOR TREATMENT OF HIP AND GROIN PAIN ASSOCIATED WITH FEMOROACETABULAR IMPINGEMENT (FAI) - Methods for treating or alleviating symptoms associated with femoroacetabular impingement (FAI) by local administration of a clostridial derivative, such as a botulinum toxin, to the hip capsule and surrounding muscle. | 10-30-2014 |
20140316009 | INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS - The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal. | 10-23-2014 |
20140315872 | NON-IRRITATING TESTOSTERONE EMULSIONS - Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease. | 10-23-2014 |
20140315828 | CROSS-LINKED SILK-HYALURONIC ACID COMPOSITIONS - Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions. | 10-23-2014 |
20140308354 | SUSTAINED RELEASE BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION - The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction. | 10-16-2014 |
20140302007 | BOTULINUM TOXIN FORMULATION - neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the | 10-09-2014 |
20140296287 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2 | 10-02-2014 |
20140294986 | Microsphere Drug Delivery System for Sustained Intraocular Release - Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed. | 10-02-2014 |
20140294803 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 10-02-2014 |
20140287988 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS - Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder. | 09-25-2014 |
20140277000 | IMPLANTABLE SILK PROSTHETIC DEVICE AND USES THEREOF - A method of using a biocompatible surgical silk mesh prosthetic device in body aesthetics and body contouring, the surgical mesh employing a knit pattern that substantially prevents unraveling and preserves the stability of the mesh device, especially when the mesh device is cut. An example prosthetic device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. the second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes. | 09-18-2014 |
20140276384 | ADIPOSE TISSUE COMBINATIONS, DEVICES, AND USES THEREOF - Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction. | 09-18-2014 |
20140275272 | PROSTAMIDES FOR ENHANCEMENT OF LEPTIN PRODUCTION - Prostamides such as bimatoprost and its pro-drugs for enhancement of leptin production and appetite suppression. | 09-18-2014 |
20140275266 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND METHODS OF USE FOR SAME - Embodiments described herein are directed to prostanoid (IP) receptor agonist compounds, including cicaprost and certain prodrugs, and methods of preparation and use for the same. Certain embodiments are directed to the use of cicaprost and certain prodrugs in the treatment of topical and ocular conditions. | 09-18-2014 |
20140275238 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS - There are provided inter alia methods and compounds useful for decreasing choroidal neovascularization in a subject in need thereof. | 09-18-2014 |
20140275200 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS - There are provided inter alia methods and compounds useful for decreasing neovascularization (e.g., choroidal neovascularization) in a subject in need thereof. | 09-18-2014 |
20140275197 | ALPHA-2 ADRENERGIC AGONIST FOR TREATING INTRAOCULAR PRESSURE AND OCULAR DISEASES THROUGH INTRAVITREAL AND INTRACAMERAL ROUTES - The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline. | 09-18-2014 |
20140275132 | PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel pyridine or pyrimidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with chemokine receptor modulation. | 09-18-2014 |
20140274963 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 09-18-2014 |
20140274873 | COMPOSITION OF A SUSTAINED-RELEASE DELIVERY AND METHOD OF STABILIZING PROTEINS DURING FABRICATION PROCESS - As described herein, controlled and sustained administration of a therapeutic agent, such as a protein through the administration of one or more microparticles, may improve treatment of conditions, such as undesirable ocular conditions. The microspheres can be formulated to provide a sustained release of a protein, while reducing the number of protein aggregates, achieving desirable release profiles, and increasing stability of the protein within the microsphere formulations. | 09-18-2014 |
20140271875 | COMPOSITIONS INCLUDING ENCAPSULATED ISOTRETINOIN AND METHODS FOR USE THEREOF - The present invention provides topical dermal compositions including microsphere encapsulated isotretinoin. Pharmaceutically acceptable salts, esters, or amides of isotretinoin are also contemplated for use in the practice of the invention. The compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne. | 09-18-2014 |
20140271780 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT - Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described. | 09-18-2014 |
20140257179 | SYRINGE FOR MIXING AND DISPENSING ADIPOSE TISSUE - A device is provided for introducing into a patient a combination of adipose tissue and an additive, for example, a hydrogel additive. The device includes a fat cartridge, an additive cartridge containing an additive, and a housing configured to receive, in a side-by-side manner, the fat cartridge and additive cartridge. A mixing tip may be included for causing mixing of the cartridge components prior to extrusion from a needle or cannula. | 09-11-2014 |
20140256945 | PHOSPHONIC ACID COMPOUNDS AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS - The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 09-11-2014 |
20140256819 | KINASE INHIBITORS - The present invention relates to compounds of formula I | 09-11-2014 |
20140256726 | PRESERVATIVE FREE BIMATOPROST AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 09-11-2014 |
20140256696 | Steroid conjugates - The present invention describes steroid conjugates. These single drug entities are formed by connecting two or more steroids via a linker. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual steroid drugs. | 09-11-2014 |
20140256694 | STEROID ANTIBIOTIC CONJUGATES - The present invention describes steroid antibiotic conjugates. These single drug entities are formed connecting a steroid moiety and two same antibiotics moieties, or a steroid moiety and two different antibiotics moieties. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
20140256685 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES - The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2). | 09-11-2014 |
20140256684 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES - The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2. | 09-11-2014 |
20140256675 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES - Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery. | 09-11-2014 |
20140256666 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS - The present invention describes single drug entities, formed by connecting an antibiotic moiety via a linker with a non-steroidal anti-inflammatory drug (NSAID) moiety. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual antibiotic and NSAID drug. | 09-11-2014 |
20140256660 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS - The present invention describes novel single drug entities, formed by the linkage of an antibiotic with a steroidal drug via a linker. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
20140256658 | Antibiotic Conjugates - The present invention describes antibiotic conjugates. These single drug entities are formed connecting one antibiotic with another antibiotic. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
20140256651 | Cyclosporine A steroid conjugates - The present invention describes Cyclosporine A/steroid hybrid analogs. These single drug entities are formed by connecting a steroid with Cyclosporine A. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
20140256612 | ANTIBIOTIC CONJUGATES DIRECTLY LINKED WITH STEROID DRUGS - The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug. | 09-11-2014 |
20140249192 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula | 09-04-2014 |
20140249153 | FIXED DOSE COMBINATION OF BIMATOPROST AND BRIMONIDINE - The present invention is directed to compositions comprising combinations of brimonidine and bimatoprost useful for lowering intraocular pressure in a patient and for the treatment of glaucoma. | 09-04-2014 |
20140249123 | EXTENDED RELEASE BIODEGRADABLE OCULAR IMPLANTS - Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer. | 09-04-2014 |
20140243973 | SOFT FILLED PROSTHESIS SHELL WITH DISCRETE FIXATION SURFACES - A soft prosthetic implant shell, such as a silicone breast implant shell, that has discrete fixation surfaces thereon for tissue adhesion. The fixation surfaces may be provided on the posterior face of the shell, as well as either on the periphery or at discrete areas on the anterior face. Band-shaped fixation surfaces may be provided on the anterior face of the shell to generally match the angle of pectoralis major or pectoralis minor muscle groups. The fixation surfaces may be roughened areas of the shell, or may be separate elements adhered to the shell. | 08-28-2014 |
20140243307 | PYRAZOLE AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to pyrazole azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-28-2014 |
20140243287 | PYRAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to pyrazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-28-2014 |
20140242258 | IMPLANTABLE MATERIALS - A textured breast implant is provided which generally includes a fluid fillable elastomeric shell having a texture defined by struts, for example, hollow struts, defining interconnected open cells. Methods of making the texture include applying a silicone dispersion to a base material and removing the base material from the coating to form a silicone-based structure comprising struts defining interconnected open cells, said struts including internal surfaces defining cavities within the struts. The method may further include the step of contacting the silicone based structure having cavities with a silicone dispersion to cause the silicone to enter and fill the cavities. | 08-28-2014 |
20140237782 | METHOD FOR MAKING A KNITTED MESH - A biocompatible surgical silk mesh prosthetic device employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh device, especially when the mesh device is cut. An example prosthetic device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. the second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes. | 08-28-2014 |
20140235685 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-BROMO-N-(IMIDAZOLIDIN-2-YLIDENE)-1H-BENZIMIDAZOL-5-AMINE FOR TREATING SKIN DISEASES - The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. | 08-21-2014 |
20140235681 | Combination therapy for glaucoma - Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α | 08-21-2014 |
20140235618 | METHODS FOR TREATMENT OF ATOPIC DERMATITIS AND INFLAMMATORY SKIN DISORDERS - The present invention provides methods for the treatment of atopic dermatitis and other inflammatory skin disorders. It has been found that topical application of alcaftadine compositions is useful for prophylaxis and symptomatic management of atopic dermatitis and associated symptoms. | 08-21-2014 |
20140235613 | SUBSTITUTED DIARYL AZETIDINE DERIVATIVES AS SPHINGOSINE RECEPTOR MODULATORS - The present invention relates to substituted diaryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-21-2014 |
20140235592 | SUBSTITUTED 6-METHOXY-4-AMINO-N-PHENYL-2-NAPHTAMIDES AS SPHINGOSINE RECEPTOR MODULATORS - The present invention relates to substituted 6-methoxy-4-amino-N-phenyl-2-naphtamides derivatives, processes for preparing them, pharmaceutical compositions to containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-21-2014 |
20140235588 | SUBSTITUTED 1H-PYRAZOL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE RECEPTOR MODULATORS - The present invention relates to substituted 1H-pyrazol-1,2,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-21-2014 |
20140235587 | SUBSTITUTED PYRAZOLES AS SPHINGOSINE RECEPTOR MODULATORS - The present invention relates to substituted pyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-21-2014 |
20140235585 | SUBSTITUTED DIARYL DERIVATIVES AS SPHINGOSINE RECEPTOR MODULATORS - The present invention relates to substituted diaryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-21-2014 |
20140234390 | SUSTAINED DRUG DELIVERY IMPLANT - Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration. | 08-21-2014 |
20140234389 | SUSTAINED DRUG DELIVERY IMPLANT - Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration. | 08-21-2014 |
20140221498 | AMINO DIOL DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to amino diol derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-07-2014 |
20140221493 | TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS - The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment. | 08-07-2014 |
20140221481 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 08-07-2014 |
20140221453 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS - The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function. | 08-07-2014 |
20140221351 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 08-07-2014 |
20140221317 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 08-07-2014 |
20140221309 | EYE DROP FORMULATION WITH ENHANCED PROPERTIES BY COMBINING SODIUM HYALURONATE WITH CARBOXYMETHYLCELLULOSE - Embodiments described herein relate to formulations for and methods of use for eye drop formulations comprising carboxymethyl cellulose (CMC) and hyaluronic acid (HA) with an improved distribution on the cornea during blinking. | 08-07-2014 |
20140213573 | NOVEL BENZYL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel benzyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 07-31-2014 |
20140213561 | OPHTHALMIC SUSPENSION FOR OCULAR USE - A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries. | 07-31-2014 |
20140206839 | CROSS LINKED HYALURONIC ACID-SILK AND USES THEREOF - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 07-24-2014 |
20140206774 | POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 07-24-2014 |
20140206701 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF - The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptor. | 07-24-2014 |
20140206652 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 07-24-2014 |
20140206626 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin exponent to the hydrophobic component is less than 0.8. | 07-24-2014 |
20140206022 | THREE-DIMENSIONAL CELL CULTURE METHODS FOR TEST MATERIAL ASSESSMENT OF CELL DIFFERENTIATION - The present specification discloses three-dimensional in vitro cell-based methods to assess a test matrix polymer ability to support differentiation of a population of cells methods of screening a material for its ability to stimulate cell growth and/or differentiation. | 07-24-2014 |
20140205649 | SOLVENT CAST FILM SUSTAINED RELEASE LATANOPROST IMPLANT - The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradable polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradable polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio. | 07-24-2014 |
20140205590 | BOTULINUM TOXIN TREATMENTS OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder. | 07-24-2014 |
20140203478 | SYSTEM AND METHOD FOR MOLDING SOFT FLUID-FILLED IMPLANT SHELLS - Systems and methods for molding shells for fluid-filled prosthetic implants, including spinning and rotating dip- or spray-mandrels during a devolatilization step to ensure an even covering. The mandrels may be spun during the dipping or spraying step, and/or afterward while a solvent evaporates until a gum state is formed. The techniques are particularly useful for forming hollow shells from silicone dispersions for soft implants, such as breast implants. | 07-24-2014 |
20140200254 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders. | 07-17-2014 |
20140200185 | CYCLOSPORIN DERIVATIVES FOR TREATING OCULAR AND DERMAL DISEASES AND CONDITIONS - The present invention provides a method for the treatment of ocular or dermal diseases and/or conditions, e.g. an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, or balanitis, psoriasis, or atopic dermatitis of the skin, said method comprising administering, topically to the eye or the skin, a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: | 07-17-2014 |
20140199366 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR NEUROPATHIES - Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma. | 07-17-2014 |
20140199288 | PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN - This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. | 07-17-2014 |
20140195265 | METHOD FOR REIMBURSEMENT OF HEALTHCARE SERVICES - Embodiments of the invention relate to methods for gaining reimbursement for provided healthcare services. | 07-10-2014 |
20140194987 | SILK COVERED BREAST IMPLANT - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 07-10-2014 |
20140194450 | TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS - The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment. | 07-10-2014 |
20140187642 | TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS - The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment. | 07-03-2014 |
20140187637 | TROMETHAMINE SALT OF BIMATOPROST ACID IN CRYSTALLINE FORM, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. | 07-03-2014 |
20140187636 | CRYSTALLINE FORMS OF BIMATOPROST ACID, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension. | 07-03-2014 |
20140187596 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN - The present invention provides a method of treating a patient suffering from pain or other FAAH mediated conditions by administering a fatty acid amide inhibiting amount of a compound represented by the formula: wherein R | 07-03-2014 |
20140180413 | SILK COVERED PROSTHESIS - Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells. | 06-26-2014 |
20140180412 | DEVICE AND METHOD FOR MAKING A VARIABLE SURFACE BREAST IMPLANT - Devices and methods are provided for making a variable textured breast implant when used in conjunction with a breast implant mandrel having a molding surface and a stem depending therefrom. | 06-26-2014 |
20140179925 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2 | 06-26-2014 |
20140179819 | POROUS MATERIALS, METHODS OF MAKING AND USES - The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices. | 06-26-2014 |
20140179752 | METHODS OF TREATING SOFT TISSUE DEFECTS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 06-26-2014 |
20140178966 | ANIMAL PRODUCT FREE SYSTEM AND PROCESS FOR PURIFYING A BOTULINUM TOXIN - Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium. | 06-26-2014 |
20140171861 | SYRINGE ASSEMBLY - An insert useful with a dermal filler syringe is provided for facilitating mixing of active agents with dermal fillers being injected into skin. | 06-19-2014 |
20140171661 | REDUCED CENTRAL CORNEAL THICKENING BY USE OF HYDROPHILIC ESTER PRODRUGS OF BETA-CHLOROCYCLOPENTANES - Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided. | 06-19-2014 |
20140171393 | NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS - The present invention relates to novel aromatic thio derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 06-19-2014 |
20140170234 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue, for example, in breast augmentation procedures. The compositions include adipose tissue and compounds that reduce tissue volume loss and increase survival rate of the adipose tissue when the composition is introduced into breast tissue. | 06-19-2014 |
20140170132 | PROPHYLATIC TREATMENT OF HERPES RECURRENCE - The present invention relates to methods for prophylactic treatment of Herpes recurrence with a Clostridial neurotoxin, such as a | 06-19-2014 |
20140163678 | METHODS FOR AUGMENTING OR RECONSTRUCTING A BREAST AND A KIT THEREFOR - Methods and systems are provided for facilitating a breast augmentation or reconstruction procedure. The methods generally include performing an incision in a breast of a patient and forming a surgical pocket in the breast, introducing, into the pocket, a mock breast implant, introducing an injectable composition adjacent the mock breast implant in the breast, and replacing the mock implant with a permanent breast implant. Kits useful to perform these methods are also provided. | 06-12-2014 |
20140161749 | COMPOSITIONS AND METHODS FOR TREATING PURPURA - Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α | 06-12-2014 |
20140156002 | METHODS FOR CREATING FOAM-LIKE TEXTURE - Methods for creating a foam-like texture on an implantable material are provided. More particularly, methods for creating foam-like texture on implantable silicone materials are provided. | 06-05-2014 |
20140155488 | COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 06-05-2014 |
20140154508 | POROGEN COMPOSITIONS, METHODS OF MAKING AND USES - The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices. | 06-05-2014 |
20140154491 | FOAM-LIKE MATERIALS AND METHODS FOR PRODUCING SAME - Described herein are foam-like materials having substantially the same physical structure of polyurethane foams but with properties that can be tailored for a particular application. Methods of forming these foam-like materials are also described. | 06-05-2014 |
20140148506 | DRUG ELATING SILICONE GEL SHEETING FOR WOUND HEALING AND SCAR REDUCTION - Provided are compositions of various silicone compounds loaded with active pharmaceutical agents, which are suitable for promoting the healing of skin wounds and the reduction or prevention of scarring. | 05-29-2014 |
20140148456 | PRESERVATIVE FREE BRIMONIDINE AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 05-29-2014 |
20140148455 | PRESERVATIVE FREE BIMATOPROST AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 05-29-2014 |
20140142184 | TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 05-22-2014 |
20140142092 | COMPOUNDS AND METHODS FOR SKIN REPAIR - The disclosure provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one mixed EP2/EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like. | 05-22-2014 |
20140142042 | SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS - A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars. | 05-22-2014 |
20140141106 | ARTIFICIAL TEARS AND THERAPEUTIC USES - The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e.g. olive oil, sesame oil, corn oil etc. | 05-22-2014 |
20140140983 | METHOD FOR TREATMENT OF AUTONOMIC NERVOUS SYSTEM DISORDERS - Botulinum toxin, among other presynaptic neurotoxins is used for the treatment of autonomic nervous system disorders such as irritable bowel syndrome. The neurotoxin is delivered to target the sympathetic ganglion. Exemplary delivery is carried out by way of injection. | 05-22-2014 |
20140135366 | ARYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to aryl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-15-2014 |
20140135365 | 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to 2-thio-1,3,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-15-2014 |
20140135293 | ALLENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to allene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-15-2014 |
20140135291 | 2-THIO-1,3,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to novel 2-thio-1,3,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-15-2014 |
20140128471 | DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 05-08-2014 |
20140128369 | NOVEL BENZYL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel benzyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-08-2014 |
20140128366 | 1,3,4-OXADIAZOLES-2-THIO AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to substituted 1,3,4-oxadiazoles-2-thio azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-08-2014 |
20140128348 | 1,3,4-OXADIAZOLES-2-THIO DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to substituted 1,3,4-oxadiazoles-2-thio derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-08-2014 |
20140128329 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS - Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein. | 05-08-2014 |
20140127784 | MODIFIED CLOSTRIDIAL TOXINS COMPRISING AN INTEGRATED PROTEASE CLEAVAGE SITE-BINDING DOMAIN - The present specification discloses modified Clostridial toxins, compositions comprising an integrated protease cleavage site-binding domain, polynucleotide molecules encoding such modified Clostridial toxins and compositions comprising di-chain forms of such modified Clostridial toxins. | 05-08-2014 |
20140127327 | PRESERVED TOPICAL FORMULATIONS WITH IMPROVED ANTIMICROBIAL ACTIVITY - A preservative consisting of a stabilized oxychloro complex and a polyol having from 3 to 6 carbons is disclosed herein. A composition comprising a stabilized chlorine dioxide. and a polyol having from 3 to 6 carbons is also disclosed herein. | 05-08-2014 |
20140121771 | INFLATABLE PROSTHESES AND METHODS OF MAKING SAME - An inflatable tissue expander or more permanent prosthesis, suitable for implantation in a breast, is provided. The tissue expander includes a puncturable, self-sealing anterior portion forming a fillable cavity, and posterior portion that is puncture resistant. The anterior portion includes a silicone-based elastomer material having a mesh embedded therein. The posterior portion includes a first composite guard and a second composite guard, each composite guard including an arrangement of puncture resistant members and a flexible substrate having a first side on which the puncture resistant members are disposed in a spaced apart fashion. | 05-01-2014 |
20140121258 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxyl}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula (I). Wherein R1, R2, R3, R4, R5, R6, X, W, X and Y are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions. | 05-01-2014 |
20140121209 | COMPOSITIONS & METHODS FOR LOWERING INTRAOCULAR PRESSURE - Disclosed herein are compositions for lowering intraocular pressure (IOP) of an eye comprising a combination IOP-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing IOP in the eye of a subject. | 05-01-2014 |
20140114122 | HYDRAULIC-MECHANICAL GASTRIC BAND - An implantable banding system for treating obesity is disclosed. The implantable banding system includes a telemetric control unit, a gastric band having at least one inner fluid compartment and an outer mechanical adjustment mechanism, the at least one inner fluid compartment being filled with a fixed volume of fluid, and the outer mechanical adjustment mechanism comprising a device configured to adjust the gastric band through a variety of diameters, an implant circuit coupled to the device and configured to receive an adjustment signal to control the operations of the device, and a sensor positioned within the at least one inner fluid compartment, configured to monitor a parameter of the fixed volume of fluid, generate an adjustment signal based on the parameter and one or more parameter control limits, and automatically activate the device based on the adjustment signal or transmit the adjustment signal to the telemetric control unit. | 04-24-2014 |
20140113974 | 7-[3,5-DIHYDROXY-2- (3-HYDROXY-5-PHENYL-PENT-1-ENYL)- CYCLOPENTYL]-N-ETHYL-HEPT-5-ENAMIDE (BIMATOPROST) IN CRYSTALLINE FORM II, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I. | 04-24-2014 |
20140113947 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE - The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient. | 04-24-2014 |
20140113946 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM - The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M | 04-24-2014 |
20140107158 | METHODS FOR TREATING COGNITIVE DISORDERS - Disclosed herein are methods of treating a patient suffering a cognitive disorder. | 04-17-2014 |
20140107153 | THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES - Disclosed herein is a stable compound having a structure: | 04-17-2014 |
20140107124 | NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES - Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma. | 04-17-2014 |
20140107102 | Ocular Allergy Treatments - Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof. | 04-17-2014 |
20140107075 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 04-17-2014 |
20140105959 | METHOD AND DEVICE FOR REDUCING DERMAL FILLER ADVERSE EVENTS - Methods and devices of aesthetically enhancing and improving appearance of aging skin are provided. Methods may include the steps of treating a skin site selected for dermal filler administration with a mechanism effective to enhance drug delivery across the skin, applying to the treated site, a device, compound or formulation including an active agent effective to reduce visible bruising due to administration of a dermal filler into the site, and administering a dermal filler into the skin site thereby reduce the appearance of wrinkles or folds in the skin site without causing significant bruising. Devices for reducing or ameliorating adverse events from dermal filler administration are also included. | 04-17-2014 |
20140105951 | SERICIN EXTRACTED FABRICS - Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties. | 04-17-2014 |
20140104272 | ANATOMICAL RECOGNITION, ORIENTATION AND DISPLAY OF AN UPPER TORSO TO ASSIST BREAST SURGERY - Various methods, techniques or modules are provided to allow for the automated analysis of the 3-D representation of the upper front torso (i) to recognize 3-D anatomical features, (ii) to orient the subject with reference to their anatomy or a display, (iii) to determine dimensional analysis including direct point-to-point lines, 3-D surface lines, and volume values, (iv) to simulate the outcome with the addition of breast implants including breast and nipple positioning, (v) to assist in the selection of the breast implants, and/or (vi) to assist in the planning of breast surgery. The automated analysis is based on the analysis of changes in a 3-D contour map of the upper torso, orientation analysis of 3-D features and planes, color analysis of 3-D features, and/or dimensional analysis of 3-D features and positions of the upper torso. | 04-17-2014 |
20140102579 | NEEDLE GUIDE - Needle guides are disclosed. An example needle guide includes a base; a housing configured to hold a container, the housing disposed on the base such that a longitudinal axis of the container is held at a first angle to vertical; and a syringe holder configured to guide insertion of a needle of a syringe into the container, the syringe holder disposed on the housing such that the syringe is inserted into the container at a second angle to the longitudinal axis of the container. | 04-17-2014 |
20140100287 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. | 04-10-2014 |
20140100212 | COMPOUNDS AS TYROSINE KINASE MODULATORS - The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors. | 04-10-2014 |
20140100199 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 04-10-2014 |
20140100197 | BICYCLIC 1, 2, 4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to bicyclic aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 04-10-2014 |
20140094662 | METHOD OF ASSESSING CAPSULAR FORMATION AND/OR CONTRACTURE - The present specification discloses methods of assessing the extent of capsular contracture around an implantable device and methods of monitoring fibrous capsular formation relating to an implantable device. | 04-03-2014 |
20140094614 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 04-03-2014 |
20140094433 | DERMAL FILLER HYDROGELS WITH VITAMIN A/CYCLODEXTRIN INCLUSION COMPLEXES - Compositions, such as hydrogel compositions, that include a hyaluronic acid, a vitamin A, and a cyclodextrin may be used as medical or cosmetic fillers, implants, or creams. For example, the compositions may be used as dermal fillers. | 04-03-2014 |
20140094431 | METHODS OF MAKING HYDROGELS FOR SOFT TISSUE AUGMENTATION - Hair-like shaped crosslinked hydrogels and methods for preparing such crosslinked hydrogels and are provided. | 04-03-2014 |
20140093957 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 04-03-2014 |
20140088703 | SOFT PROSTHETIC IMPLANT MANUFACTURING PROCESS - A soft prosthetic implant, for example, a breast implant, having a shell filled with a fluid. One or more components of the soft prosthetic implant receive a unique identifier for traceability during the manufacturing process. The unique identifier is placed on one component, such as a patch molded-in-place with a shell to form a soft prosthetic implant. Information about the respective components, as well as process parameters, can be stored on the unique identifier for later reference. The unique identifier may be a two-dimensional printed label or laser-etched characters, or may be a three-dimensional embossed or indented region. The unique identifier may be a separate label attached to the respective component, or may be formed in the component, such as with embossing. | 03-27-2014 |
20140088702 | TISSUE EXPANDER WITH SELF-HEALING ANTERIOR SIDE - A tissue expander includes an elastomeric shell having an anterior inside surface and a posterior inside surface with a self-healing layer abutting only a portion of the anterior inside surface. The layer is spaced apart from the posterior inside surface while facilitating folding of the shell prior to insertion into a tissue pocket and also enabling inflation of the shell subsequent to insertion by a fluid injected between the self healing layer and posterior surface. | 03-27-2014 |
20140088700 | METHOD FOR USING A SILK DERIVED BIORESORBABLE SCAFFOLD IN BREAST RECONSTRUCTION - A method of using a silk derived medical device in a two stage breast reconstruction procedure. | 03-27-2014 |
20140079655 | COMPOSITIONS FOR ENHANCING NAIL HEALTH - The present invention is directed to compositions and methods for enhancing the health of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to enhance nail health. The composition is also effective in strengthening and growing nails. | 03-20-2014 |